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Desmin-related myopathy and cataract are both
caused by the R120G mutation in aB-crystallin. Desmin-
related myopathy is one of several diseases character-
ized by the coaggregation of intermediate filaments
with aB-crystallin, and it identifies intermediate fila-
ments as important physiological substrates for aB-
crystallin. Using recombinant human aB-crystallin, the
effects of the disease-causing mutation R120G upon the
structure and the chaperone activities of aB-crystallin
are reported. The secondary, tertiary, and quaternary
structural features of aB-crystallin are all altered by the
mutation as deduced by near- and far-UV circular di-
chroism spectroscopy, size exclusion chromatography,
and chymotryptic digestion assays. The R120G aB-crys-
tallin is also less stable than wild type aB-crystallin to
heat-induced denaturation. These structural changes
coincide with a significant reduction in the in vitro
chaperone activity of the mutant aB-crystallin protein,
as assessed by temperature-induced protein aggrega-
tion assays. The mutation also significantly altered the
interaction of aB-crystallin with intermediate fila-
ments. It abolished the ability of aB-crystallin to pre-
vent those filament-filament interactions required to in-
duce gel formation while increasing aB-crystallin
binding to assembled intermediate filaments. These ac-
tivities are closely correlated to the observed disease
pathologies characterized by filament aggregation ac-
companied by aB-crystallin binding. These studies pro-
vide important insight into the mechanism of aB-crys-
tallin-induced aggregation of intermediate filaments
that causes disease.
Desmin-related myopathy (DRM)1 can be caused by muta-
tions either in the intermediate filament protein desmin, or in
the small heat shock protein aB-crystallin. Although several
mutations in the intermediate filament protein desmin have
been linked with DRM (1, 2), so far only a single mutation,
R120G, in the small heat shock protein aB-crystallin has been
identified (3). A characteristic disease pathology links the dif-
ferent causes of DRM, which consists of aggregates of interme-
diate filaments containing aB-crystallin present in the muscle
cells of affected individuals (3, 4).
Other diseases, such as Alexander’s disease (5) and drug-
induced hepatitis (6), are also characterized by intermediate
filament aggregates. These aggregates are typically co-associ-
ated with aB-crystallin (7) despite the fact that they involve
different intermediate filament proteins. This suggests that
the association of aB-crystallin with intermediate filament ag-
gregates is independent of the specific intermediate filament
protein but is rather a generic response to this pathological
rearrangement of intermediate filaments. These data establish
a clear link between aB-crystallin, intermediate filaments, and
the disease-induced aggregation of intermediate filaments (8).
The mechanism of intermediate filament aggregation and the
role of small heat shock proteins in this process has yet to be
addressed.
The recent assessment of sHSP activity in vitro has been
based upon chaperone assays using either heat (9–11) or chem-
ically unfolded substrates (12). These have been extremely
useful for studying the role of ATP (13), post-translational
modifications (11, 14–17), and specific aB-crystallin residues
(18–22) in the chaperone activity of sHSPs. These studies
mimic the role of sHSPs in stressed cells, but they do not
identify the physiological targets or the role of sHSPs in un-
stressed cells.
The sHSPs are expressed in unstressed cells (8, 23–25) and
sometimes at very high levels (26, 27). In unstressed, non-
diseased cells of muscle (23), astrocyte (24, 25), and epithelial
and lenticular origins (27), aB-crystallin is found associated
with intermediate filaments. In the eye lens, there is a unique
cytoskeletal filament that is a stable complex of a-crystallin,
comprising both aB- and aA-crystallin, and lens intermediate
filaments (28). This is called the beaded filament. Similar
structures can be generated in vitro under appropriate coas-
sembly conditions (29). These studies show that the association
of sHSPs with intermediate filament networks is not just a
stress-induced event (30), but is a feature of normal cells, and
suggest a general role for sHSPs in intermediate filament
biology.
Small HSPs bind to assembly competent intermediate fila-
ment proteins. This was demonstrated in the lens where a
soluble complex of a-crystallin and intermediate filament pro-
teins was immunopurified from lens cytosol (27, 31). It was
subsequently demonstrated that sHSPs could inhibit GFAP as
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well as vimentin assembly in vitro (27). These data indicated
that the association of sHSPs with intermediate filament pro-
teins is not restricted to the filamentous form, but includes
soluble intermediate filament complexes. From these observa-
tions, it is clear that sHSPs have the potential to influence
intermediate filament assembly (29).
Recently, another aspect of the interaction of sHSPs with
intermediate filaments was identified (32). Using a simple vis-
cosity-based assay, sHSPs were shown to prevent gel formation
by intermediate filaments, presumably by blocking non-cova-
lent filament-filament interactions (32). These studies sug-
gested a physiologically important link between intermediate
filaments and sHSPs. In a cellular context, this link may pre-
vent inappropriate interactions between bundled intermediate
filaments (32). Abrogation of this sHSP function could lead to
intermediate filament aggregate formation. This is not only
relevant to DRM but also to other human diseases where this
phenotype is a pathological hallmark such as Alexander’s
disease.
In this study, the structural and functional properties of the
R120G aB-crystallin are compared with those of the wild type
protein. Using several different in vitro assays, the effect of the
mutation upon the chaperone activity of aB-crystallin has been
studied. The UVCD, size exclusion chromatography and prote-
olysis studies all suggest that the mutation has affected the
secondary, tertiary, and quaternary structure of aB-crystallin.
The mutation also causes a significant reduction in the heat-
induced denaturation and a reduction the in vitro chaperone
activity of the protein. In order to understand how the aB-
crystallin mutation could cause intermediate filament aggre-
gation as seen in DRM, its effect upon the association with
intermediate filaments was studied. The data show that R120G
aB-crystallin was incapable of preventing filament-filament
interactions that lead to the formation of an intermediate fila-
ment gel in vitro. This was accompanied by an apparent in-
crease in the binding of R120G aB-crystallin to intermediate
filaments. These data suggest that DRM resulting from the
R120G mutation in aB-crystallin occurs as a progressive accu-
mulation of intermediate filament aggregates brought about by
the altered interaction of aB-crystallin with intermediate
filaments.
MATERIALS AND METHODS
Expression Constructs for Recombinant aB-crystallins—Total RNA
was isolated from a sample of human soleus muscle (RNeasy kit, Qia-
gen) and converted into cDNA (Life Technologies, Inc.; Superscript kit).
Human aB-crystallin cDNA was amplified from this cDNA using oligo-
nucleotides 59-AGCCACCATGGACATCGC-39 and 59-CTATTTCTT-
GGGGGCTGCG-39 as forward and reverse primer, respectively. The
amplified product was cloned into the vector pGEM®-T Easy (Promega)
and the sequence confirmed against the GenBanky data base entry
(accession no. S45630). The R120G mutation was introduced by two-
step polymerase chain reaction using the pGEM-T Easy human aB-
crystallin wild type vector as a template in the first amplification
reaction. Overlapping, complementary oligonucleotides were con-
structed containing the desired A 3 G mutation at nucleotide position
358 as well as a silent A 3 G mutation at nucleotide position 363,
59-TTCCACGGGAAGTACCGGATCCCAGC-39 and 59-CCGGTACTTC-
CCGTGGAACTCCCTGGAGATGAA-39. Using all four oligonucleotides
the mutated aB-crystallin cDNA was created in two consecutive ampli-
fications, then subcloned. After verification of the sequences both the
wild type and R120G aB-crystallin cDNAs were subcloned into the NdeI
and EcoRI sites of the vector pET23b (Novagen).
Expression of Recombinant aB-Crystallins—Recombinant human
aB-crystallins were expressed in BL21plysS(DE3) in the expression
vector pET23b. Recombinant protein expression was induced using 0.5
mM isopropyl-1-thio-b-D-galactopyranoside for 4 h once the cultures had
reached an OD600 of 0.6. Harvested bacterial pellets were resuspended
in TEN buffer (50 mM Tris-HCl, pH 8, 1 mM EDTA, 300 mM NaCl, 0.2
mM PMSF, and 0.1% v/v of protease inhibitor mixture (Sigma)) and
lysed by several freeze/thaw cycles. A supernatant fraction containing
the soluble proteins including the recombinant sHSPs was prepared by
centrifuging the lysate at 15,000 rpm in a JA20 rotor at 4 °C for 30 min.
The supernatant was then dialyzed against column buffer.
Preparation of GFAP, Native, and Recombinant aB-crystallins—
GFAP was purified from porcine spinal cord by axonal flotation as
described previously (33). GFAP was then separated from the other
neuronal intermediate filament proteins using DE52 (Whatman) in 8 M
urea, 10 mM Tris-HCl, pH 8, 5 mM EDTA, and 25 mM 2-mercaptoetha-
nol. The proteins were eluted with a 0–200 mM NaCl linear gradient.
All column procedures were carried out at room temperature. Recom-
binant aB-crystallin was purified by both non-denaturing (34) and
denaturing methods. In the latter, two diethylaminoethyl (DEAE) col-
umn steps were used. The supernatant fraction obtained from the
bacteria was loaded onto the first column comprising TSK-DEAE 650M
(Merck Ltd.) in 20 mM Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM MgCl2, 1 mM
EDTA, 1 mM DTT, 0.2 mM PMSF and eluted with a 20–250 mM NaCl
gradient. The sHSP-enriched fractions were pooled and dialyzed into
buffer containing 6 M urea, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1 mM
DTT, 0.2 mM PMSF. This was then loaded onto a DE52 column equil-
ibrated in the same buffer. Proteins were eluted with a 0–200 mM NaCl
gradient. All column steps were carried out at 4 °C. Column fractions
were checked for homogeneity by SDS-PAGE. Protein concentrations
were determined by the Bradford protein assay.
Analytical Size Exclusion Chromatography—Analytical size-exclu-
sion chromatography was performed on a Biosep-SEC-S4000, 7-mm,
300 3 7.8-mm column using a Hewlett-Packard high performance liq-
uid chromatograph with the following mobile phase: 0.1 M potassium
phosphate, pH 7.0 and 0.2 M NaCl, at a flow rate of 0.5 ml/min. High
molecular weight protein standards (Amersham Pharmacia Biotech)
were used to calibrate the column. The standard deviation of the mo-
lecular masses of wild type aB-crystallin/aB-crystallin mutants was
determined from the peak width at its half-height in six independent
experiments.
Proteolytic, Spectroscopic, and in Vitro Chaperone Analyses—Prote-
olysis of wild type aB-crystallin/aB-crystallin mutants was performed
as described previously (22, 35). CD spectra were measured as de-
scribed previously (36, 37). The presented CD spectra are the average of
16 scans, smoothed by polynomial curve fitting. The fit was checked
with a statistical test so that the original data was not over-smoothed.
To calculate molar ellipticity, a residue molecular weight of 115 was
assumed. The proteins were dissolved in 20 mM sodium phosphate
(pH7.1) and used at concentrations of 0.5 and 1.0 mg/ml for far- and
near-UVCD, respectively, as determined from calculated extinction co-
efficients based on a protein amino acid sequence as described previ-
ously (38, 39). The pathlength of the cells was 10 mm for near-UVCD
and 1.0 mm for far-UVCD spectroscopy.
Temperature-dependent precipitation of wild type and R120G aB-
crystallin was measured in a Beckman DU640 spectrophotometer
equipped with a Peltier temperature controlled cuvette holder. The rate
of temperature increase was 0.1 °C/min. Proteins were dialyzed into 20
mM sodium phosphate, pH 7.1, and the concentration adjusted to 0.5
mg/ml prior to the assay. First derivative calculation was used to
determine the temperature at which 50% precipitation had occurred.
Temperature-induced aggregation assays using citrate synthase (10)
and alcohol dehydrogenase (11) as target proteins were performed as
described (13, 40).
Intermediate Filament Assembly, Binding, and Viscosity Assays In-
volving aB-crystallin—The sedimentation assay as developed by
Nicholl and Quinlan (27) was used to assess the ability of sHSPs to
inhibit intermediate filament assembly. Purified porcine GFAP was
used for these studies. aB-crystallins were added to GFAP in 8 M urea,
20 mM Tris-HCl, pH 8.0, 5 mM EDTA, 25 mM 2-mercaptoethanol prior to
the assembly assay. The final dialysis was against assembly buffer: 10
mM Tris-HCl, pH 7.0, 25 mM 2-mercaptoethanol, 50 mM NaCl. The
experiments were performed at room temperature. Dialysates were
layered onto a 0.85 M sucrose cushion in the assembly buffer and
centrifuged at 80,000 3 g for 30 min at 20 °C in a Beckman TLA-55 rotor
using a TL100 benchtop ultracentrifuge. The pellet and supernatant
fractions were compared by SDS-PAGE as described previously (27).
For the intermediate filament binding assay, aB-crystallins were
again mixed with GFAP in 8 M urea, 20 mM Tris-HCl, pH 8.0, 5 mM
EDTA, 25 mM 2-mercaptoethanol and then stepwise dialyzed into 10
mM Tris-HCl, pH 8.0, 25 mM 2-mercaptoethanol. Assembly of the GFAP
intermediate filaments and binding of the aB-crystallins was then
induced by addition of a 20-fold concentrated binding buffer (BB) to give
a final concentration of 100 mM imidazole-HCl, pH 6.8, 0.5 mM DTT and
incubation at the indicated temperature.
The gel formation assay was based upon a method used to monitor
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actin binding protein activity by falling ball viscometry (41). Filament
assembly was promoted exactly as described for the binding assay by
addition of the 20-fold concentrated BB. 100 ml of sample was loaded
into a glass tube to be used in the viscosity assay. This was then
immersed in a 37 °C water bath for 1 h prior to conducting the gel
formation assay. A ball was then placed into the tube, and the ability of
the solution to support the ball was monitored.
Electron Microscopy—Protein samples were diluted to 100–200 mg/
ml, and negatively stained using 1% w/v uranyl acetate. Grids were
examined in a Jeol 1200EX TEM, using an accelerating voltage of
80 kV.
RESULTS
Structure and Stability Characteristics of the R120G aB-
crystallin Compared with Wild Type—The effect of the disease
causing mutation R120G on the structure of aB-crystallin was
examined using near- and far-UVCD spectroscopy. The wild
type and mutant aB-crystallin were expressed in Escherichia
coli using a pET-based vector system and purified to homoge-
neity by ion exchange chromatography. The sample purity was
assessed by SDS-PAGE and is presented in Fig. 1.
Using recombinantly produced proteins, the far-UVCD spec-
trum (200–250 nm) was measured for both wild type and
mutant aB-crystallin (Fig. 2, A and B). At 25 °C (Fig. 2A), the
far-UVCD spectrum of wild type aB-crystallin contained a peak
minimum at approximately 215 nm that is consistent with
previous UVCD analyses showing a high percentage of b-sheet/
b-turn structure in aB-crystallin (34, 37, 42). When tested
under identical conditions, the R120G mutant displayed a peak
minimum that was shifted to a slightly shorter wavelength and
had a significant (44%) increase in negative molar ellipticity in
comparison to wild type aB-crystallin at 220 nm (Fig. 2A). A
second measurement was made for both proteins at 45 °C to
assess protein stability at temperatures utilized in the chaper-
one assays (Fig. 2B). While the magnitude of the peak mini-
mum (215 nm) for wild type aB-crystallin increased approxi-
mately 22% at 45 °C, there was no increase for the R120G
mutant (Fig. 2B).
At 25 °C, the near UVCD spectrum of wild type aB-crystallin
included four positive ellipticity peaks below 290 nm and a
large negative peak at approximately 295 nm (Fig. 3A), con-
sistent with past studies using aB-crystallin (34, 37, 42). In
stark contrast, peaks below 290 nm in the near-UVCD of the
R120G mutant were shifted significantly toward negative el-
lipticity values at 25 °C and only a small negative peak was
observed at 295 nm (Fig. 3A). For wild type aB-crystallin,
increasing the temperature from 25 to 45 °C resulted in a large
shift in ellipticity from positive to negative values below 290
nm, but had essentially no effect on the ellipticity of the 295 nm
peak (Fig. 3B). For the R120G mutant, an increase from 25 to
45 °C resulted in only a modest shift toward negative ellipticity
values below 290 nm, and did not significantly affect the ellip-
ticity at 295 nm (Fig. 3B). Both the far- and near-UVCD data
indicate that the R120G mutation has altered the secondary
and tertiary structure of the aB-crystallin.
The quaternary structure of R120G aB-crystallin was al-
tered, as assessed by six independent size exclusion chroma-
tography analyses. The protein complexes formed by the
R120G aB-crystallin mutant were larger (Mr 5 823,000 6
131,000) compared with the wild type (Mr 5 633,000 6 80,000)
and more disperse, as seen by the broader size distribution
given by the standard deviations.
Since the structure of aB-crystallin was affected by the
R120G mutation, we decided to assess its temperature stabil-
ity. Protein aggregation was detected by light scattering (Fig.
4) and showed that both wild type and R120G aB-crystallin did
not aggregate up to 55 °C. Above this temperature, the mu-
tated protein started to aggregate with precipitation 50% com-
plete at 57.2 °C, whereas the wild type aB-crystallin remained
soluble up to 63 °C, showing 50% precipitation at 64.5 °C. Fur-
thermore, the aggregation of the R120G aB-crystallin occurred
over a wider temperature range than that of the wild type
protein (Fig. 4). Thus, the mutation does appear to affect the
stability of the protein, but only at higher (.55 °C), non-phys-
FIG. 1. SDS-PAGE analysis of purified wild type aB-crystallin
and mutant R120G aB-crystallin. A 12% w/v gel was used as the
separating gel and proteins were visualized using the dye, Coomassie
Blue R250. Molecular size standards (lane M; Mr 3 10
23) are shown and
labeled adjacent to lane 1. Lane 1, overexpression of wild type aB-
crystallin in E. coli; lane 2, 1 mg of purified wild type aB-crystallin; lane
3, 1 mg of R120G aB-crystallin. Position of the aB-crystallin is indicated
by an arrow.
FIG. 2. Far-UV CD spectra of wild type aB-crystallin and mu-
tant R120G aB-crystallin at 25 and 45 °C. The spectra at 25 (OO)
and 45 °C (- - -) for wild type aB-crystallin (A) and R120G aB-crystallin
(B) are shown and represent an average of 16 scans, smoothed by
polynomial curve fitting. The protein concentrations were 0.5 mg/ml,
and the pathlength of the cell was 1.0 mm. The CD molar ellipticity
units are degrees cm2/dmol.
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iological temperatures.
To assess whether the R120G mutation affected the stability
of aB-crystallin below 55 °C, the temperature dependence of
the ellipticity at 205 and 217 nm was studied by far-UVCD
(data not shown). A gradual conformational transition was
shown between 25 °C and 55 °C for the wild type, but not the
mutated aB-crystallin. This is consistent with the far-UVCD
spectra (Fig. 2, A and B, cf. spectra at 25 °C versus 45 °C) and
indicates that the stability of the mutated protein was not
affected below 55 °C.
The Effect of the R120G Mutation upon the Chymotryptic
Digestion of aB-crystallin—Chymotrypsin has been used to
assess the susceptibility of aB-crystallin to proteolysis (22, 35).
ATP has been shown to increase the protection of some of these
sites in the a-crystallin domain against chymotryptic digestion
(22, 35). These assays were used to evaluate the effects of the
R120G mutation upon the availability of the chymotryptic sites
for digestion as another indicator of changes in the structural
characteristics of aB-crystallin (Fig. 5). The R120G mutation
did make the chymotryptic sites more accessible compared with
the wild type (Fig. 5), as the R120G mutant was digested faster
than wild type aB-crystallin. The pattern of proteolytic prod-
ucts produced was qualitatively similar but not the same. Pro-
tection of the chymotrypsin sites was afforded upon addition of
ATP to both the R120G and wild type aB-crystallin (Fig. 5).
Thus, at this level, the differences in the digestion character-
istics of R120G aB-crystallin suggested that there had indeed
been some structural changes as a result of the mutation, but
these did not appear to significantly alter the region(s) of aB-
crystallin involved in interacting with ATP.
In Vitro Chaperone Assays—Prior to the discovery of the
physiological substrates for aB-crystallin, in vitro assays were
developed based upon heat-induced aggregation of proteins to
assess the chaperone activity of aB-crystallin. Two were se-
lected to cover a range of chaperone: substrate concentrations
and also a range of temperatures (10, 11). As shown in Table I,
R120G aB-crystallin was worse than the wild type aB-crystal-
lin in both chaperone assays. The R120G mutant was also
tested at molar ratios of 2:1 and 10:1 (protein:aB-crystallin)
using citrate synthase as the assay substrate and gave similar
results to those obtained at a 1:1 ratio (Table I). In addition, at
both 10:1 and 5:1 (protein:aB-crystallin) in the alcohol dehy-
drogenase-based chaperone assay, similar results to the 20:1
ratio were obtained (Table I). Therefore, it is reasonable to
expect that the mutation will compromise the ability of aB-
crystallin to perform its chaperone role in muscle and lens cells.
Intermediate Filament Assembly, Binding, and Gel Forming
Assays—As demonstrated by the discovery of the disease caus-
FIG. 3. Near-UV circular dichroism spectra of wild type aB-
crystallin and mutant R120G aB-crystallin at 25 and 45 °C. The
spectra for wild type aB-crystallin (A) and R120G aB-crystallin (B) are
shown and represent an average of 16 scans, smoothed by polynomial
curve fitting. The protein concentrations were 1.0 mg/ml, and the path-
length of the cell was 10.0 mm. The CD molar ellipticity units are
degrees cm2/dmol. Spectra for both aB-crystallins were obtained at 25
(OO) and 45 °C (- - -).
FIG. 4. Temperature stability of wild type and R120G aB-crys-
tallin. Aggregation of wild type (OO) and R120G (- - -) aB-crystallin
was assessed as a function of temperature from 25 to 85 °C by light
scattering at 360 nm. Protein concentration was 0.5 mg/ml in 20 mM
sodium phosphate, pH 7.1. The temperature was increased by 0.1 °C/
min. Temperatures at midpoint of precipitation were calculated to be
64.5 and 57.2 °C for wild type and R120G aB-crystallin, respectively.
Note the different slopes of precipitation for the wild type and the
mutant proteins.
FIG. 5. SDS-PAGE analysis of the chymotryptic digestion of
wild type aB-crystallin and R120G aB-crystallin in the absence
(NO ATP) and presence of ATP (PLUS ATP) at 37 °C. Samples
were taken over a 30-min time course. In the absence of ATP, the
pattern of proteolysis for R120G aB-crystallin was similar but not
identical to the pattern observed for wild type aB-crystallin. Substan-
tial increase in the susceptibility to proteolysis was noted for R120G
aB-crystallin. The pattern of proteolysis obtained for R120G aB-crys-
tallin in the presence of ATP resembled that of wild type aB-crystallin,
although again the mutant was more susceptible than the wild type
protein. These data suggest that the mutation certainly changed acces-
sibility to the chymotryptic cleavage sites in aB-crystallin. Undigested
protein is indicated (*). Molecular size markers are indicated (l) and
correspond to 36.5, 31, 21.5 14.4, 6 and 3.5 kDa.
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ing mutation in aB-crystallin, intermediate filaments are a
physiological target of aB-crystallin. Three assays had been
developed that assess the interaction of aB-crystallin with in-
termediate filament proteins at different levels (32). These are
the ability of aB-crystallin to (a) inhibit filament assembly, (b)
bind to and co-sediment with intermediate filaments, and (c)
prevent filament-filament interactions as measured by falling
ball viscometry (32). The effect of the mutation R120G upon
aB-crystallin chaperone activity was tested using these assays.
The intermediate filament protein, GFAP, was used. GFAP is a
physiologically relevant target because of the formation of
Rosenthal fibers, which contain GFAP filaments coaggregated
with aB-crystallin in the neurodegenerative disease Alex-
ander’s disease (5). It is also a type III intermediate filament
protein closely related to desmin (43) with similar structural
features and mechanisms of assembly.
In Figs. 6 and 7, the effect upon intermediate filament as-
sembly (Fig. 6) and the ability to bind to intermediate filaments
(Fig. 7) was examined. These assays are conducted at different
pH and salt conditions to optimize for the inhibition of assem-
bly and binding to intermediate filaments, respectively (30, 32).
As can be seen in Fig. 6, R120G aB-crystallin was reduced in its
ability to inhibit the assembly of the intermediate filament
protein, GFAP. Compared with the assembly of GFAP in the
FIG. 6. Effect of wild type and R120G aB-crystallin on GFAP
assembly in vitro. In the assembly inhibition assay, GFAP was as-
sembled in vitro (A) in the presence of wild type aB-crystallin (B) and
R120G aB-crystallin (C) in a molar ratio of 1:2 at 22 °C. The superna-
tant (S) and pellet fractions (P) were analyzed by SDS-PAGE and
stained with Coomassie R250. The positions of GFAP and aB-crystallin
are indicated (B and C). Under these conditions of assembly, most of the
GFAP is sedimented (A, lane 2), with only a small proportion of the
protein remaining in the supernatant (A, lane 1). Contrast this result to
the assembly of GFAP in the presence of aB-crystallin (B), where .50%
of the GFAP remains in the supernatant (B, lane 3). Notice that using
these assay conditions, nearly all the wild type aB-crystallin remained
in the supernatant fractions in the absence (B, lane 1) and presence of
GFAP (B, lane 3). In the presence of R120G aB-crystallin (C), .80% of
the GFAP is found in the pellet (P; C, lane 4). In the presence of R120G
aB-crystallin, the soluble GFAP remaining in the supernatant (C, lane
3) is reduced compared with the coassembly of GFAP with wild type
aB-crystallin (B, lane 3) but greater than the control assembly for
GFAP (A, lane 1). Notice too that the R120G aB-crystallin bound to the
filaments in the pellet fraction (C, lane 4) in complete contrast to wild
type aB-crystallin (B, lane 4) under similar experimental conditions. In
the absence of GFAP filaments, most R120G aB-crystallin remained
soluble (C, lane 1) with only a very small proportion sedimenting under
these conditions (C, lane 2).
FIG. 7. Binding of wild type and R120G aB-crystallin to GFAP
filaments in vitro. In this assay, the GFAP assembly was conducted
under conditions that promoted aB-crystallin binding to intermediate
filaments (32). The binding is a temperature-dependent process (30,
32), and the three temperatures selected are indicated above the rele-
vant gel lanes (A–C). The pellet (P) and supernatant (S) fractions were
analyzed by SDS-PAGE and stained with Coomassie Blue R250. GFAP
assembled efficiently into filaments under these assay conditions at
temperatures of 22, 37, and 44 °C (A). Most of the GFAP is present in
the pellet fractions (A, lanes 2, 4, and 6, labeled P). The small proportion
of GFAP remaining in the supernatant (A, lanes 1, 3, and 5, respec-
tively, labeled S) varies with temperature. In the absence of GFAP, wild
type (B, lanes 1, 3, and 5) and R120G aB-crystallin (C, lanes 1, 3 and 5)
remained almost entirely soluble (labeled S). When GFAP is included in
the assay, both wild type aB-crystallin (B, cf. lanes 8, 10, and 12) and
R120G aB-crystallin (C, cf. lanes 8, 10, and 12) sedimented with the
GFAP filaments. This was temperature-dependent, as an increasing
proportion of wild type aB-crystallin and R120G aB-crystallin was
found in the pellet fractions (B and C, lanes 8, 10, and 12). Note that in
the presence of GFAP, an appreciable proportion of the R120G aB-
crystallin was pelletable even at 22 °C (C, lane 8). At 44 °C, all the
R120G aB-crystallin was present in the pellet fraction (C, lane 10). The
wild type aB-crystallin was found in the pellet fractions at 37 °C (B,
lane 10) and 44 °C (B, lane 12), but larger proportion remained in the
soluble fractions at both temperatures (B, lanes 9 and 11, cf. lanes 11
and 12).
TABLE I
The chaperone activities of aB-crystallin and R120G aB-crystallin
compared using the alcohol dehydrogenase and citrate
synthase assays
The R120G aB-crystallin was worse in all instances than the wild
type aB-crystallin.
Protein assay
% Protein aggregation
Wild type
aB-crystallin
R120G aB-
crystallin
Alcohol
dehydrogenase
(ADH): protein
ratio 5 20:1
(ADH:aB); assay
temperature 5
37 °C
29 6 2 90 6 7
Citrate synthase:
protein ratio 5
1:1; assay
temperature 5
45 °C
9 6 1 37 6 6
TABLE II
Summary of the data collected for the effect of aB-crystallin and the
R120G mutant on gel formation by intermediate filaments as
monitored by a falling ball viscometry assay
GFAP can form a protein gel capable of supporting a small ball
bearing. Including aB-crystallin in with GFAP prevented gel formation
and allowed the ball to drop to the bottom of the tube. The R120G
mutation abrogated this activity of aB-crystallin.
Chaperone added to assay
GFAP gel formation as
indicated by the ball position
in the viscometer
No addition Top
aB-crystallin Bottom
R120G aB-crystallin Top
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FIG. 8. Visualization of intermediate filaments assembled in the presence of wild type and R120G aB-crystallin. Samples were taken
at the completion of the viscosity assay and processed using the negative staining technique for electron microscopy. In the presence of wild type
aB-crystallin (A), the intermediate filaments formed were long and sometimes had aB-crystallin particles attached (arrows). The filaments were
generally not clumped in this preparation. In contrast, filaments co-assembled in the presence of R120G aB-crystallin (B) were clumped (large
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absence of aB-crystallin (Fig. 6, lanes 1 and 2), the R120G
aB-crystallin was still able to partially inhibit GFAP assembly
(Fig. 6, lanes 3 and 4). Moreover, a sizeable proportion of
R120G aB-crystallin was found in the pellet fraction (Fig. 6C,
lane 4), even at 22 °C, the temperature of this assay. The wild
type aB-crystallin remained almost completely soluble under
these conditions (Fig. 6B, lane 4). This was the first indication
that R120G aB-crystallin bound more avidly to intermediate
filaments than the wild type protein.
The increased binding of R120G aB-crystallin (Fig. 7C) to
GFAP filaments compared with the wild type protein (Fig. 7B)
was a dramatic effect of the mutation. Even at 37 °C, R120G
aB-crystallin was found to bind almost completely to the pel-
letable GFAP filaments, whereas the wild type aB-crystallin
was only partially bound (,20%). This increased binding was
consistent at different molar ratios, from 1:2 to 2:1 (sHSP to
GFAP, respectively) and was apparently unaffected by the
presence of 1 mM ATP (data not shown).
The increased binding of R120G aB-crystallin to intermedi-
ate filaments might be expected to increase its ability to pre-
vent filament-filament interactions either indirectly by steric
hindrance or directly by obscuring the filament-filament inter-
action sites. Using falling ball viscometry, this hypothesis was
tested. The assay was developed so that GFAP forms a protein
gel in the tube in the absence of aB-crystallin. The buffer
conditions are the same as those used for the filament binding
assay. This gel is capable of supporting the ball used in the
viscosity assay. Addition of aB-crystallin prevents gel forma-
tion and so permits the ball to sink to the bottom of the tube
(32). This is the result of inhibiting non-covalent filament-
filament interactions rather than preventing filament forma-
tion as these assay conditions were similar to those used in the
filament binding assay (Fig. 7), where no loss of sedimentable
GFAP was observed (see also Ref. 32). As expected, after as-
sembly of GFAP in the absence of sHSP in the control tube, a
gel formed preventing the ball from falling. The presence of
wild type aB-crystallin in the assay mixture at a 2:1 molar ratio
to GFAP prevented the filaments formed from supporting the
ball in the viscometer. In contrast, the mutant R120G aB-
crystallin appeared completely ineffective at inhibiting gel for-
mation and thus the ball was unable to enter the viscometer.
Similar results were obtained for the ratios 1:2 and 2:1, sHSP
to GFAP, respectively, and in the presence of 1 mM ATP (data
not shown). Table II summarizes data obtained from three
separate experiments.
The data from the viscosity assays have demonstrated that
the R120G mutation abolished the ability of aB-crystallin to
prevent gel formation by failing to inhibit filament-filament
interactions required in this process, despite the increased
ability of the mutant R120G aB-crystallin to bind to interme-
diate filaments (Fig. 7).
Visualization of the aB-crystallin Intermediate Filament
Complex by Electron Microscopy—To examine the association
of aB-crystallin with the GFAP filaments during the binding/
viscosity assays, samples were examined using negative stain-
ing techniques and electron microscopy (Fig. 8). At 37 °C, lim-
ited binding of wild type aB-crystallin to GFAP filament was
observed (Fig. 8A, arrows), whereas the R120G aB-crystallin
particles were very closely associated with filaments (Fig. 8B,
arrows) with no particles left unbound. In the absence of GFAP
filaments, both wild type (Fig. 8C) and R120G aB-crystallin
(Fig. 8D) formed discrete particles approximately 15–20 nm in
diameter (Fig. 8, C and D, arrows). These observations corre-
lated with the binding assay results (Fig. 7, B and C), where
almost all of the mutant aB-crystallin bound the GFAP fila-
ments compared with a much smaller proportion of the wild
type protein. From the electron micrographs, it appears that
the increased binding of the mutant aB-crystallin resulted in a
very extensive coating of the intermediate filaments, leading to
filament bundling (Fig. 8B).
DISCUSSION
The R120G mutation in aB-crystallin affects a highly con-
served residue among the whole sHSP family (44, 45). It is
important for the function of aA- and aB-crystallin as mutating
this residue causes the human diseases, cataract (46) and DRM
(3), respectively. Other mutational studies using the Mycobac-
terium tuberculosis sHSP, HSP16.3, and the mammalian
sHSPs HSP27 and aA-crystallin (21) also show this highly
conserved arginine residue is structurally very important as it
is part of a b-strand involved in subunit interactions (21).
Recently, the crystal structure of the Methanococcus jannaschii
sHSP, HSP16.5, has been described (47), and this provided the
first atomic details of this conserved arginine residue. From
these data, a direct or indirect role for the disease causing
arginine residue in subunit-subunit interactions was proposed
(48). Although a recent study reported on the structural and
chaperone-like properties of R120G aB-crystallin (49), we ini-
tiated our studies to investigate the interaction with interme-
diate filaments, the physiologically relevant target of aB-crys-
tallin given the fact the mutation causes intermediate filament
aggregation in the disease DRM (3).
Secondary, Tertiary, and Quaternary Structure of aB-crys-
tallin Is Altered by the Mutation R120G—The far- and near-
UVCD data presented here for the recombinant aB-crystallin
(Figs. 2 and 3) correlate well with previously published data
(22, 34, 37, 42). Increasing the temperature from 25 to 45 °C
resulted in shifts in ellipticity values in the far- (50) and
near-UV (50, 51) for wild type aB-crystallin that are consistent
with a conformational change. The far- and near-UVCD spectra
obtained for the R120G aB-crystallin demonstrated that the
mutation affected the secondary and tertiary structure of the
protein. Interestingly, the UVCD spectrum of R120G aB-crys-
tallin at 25 °C appeared similar to that obtained for the wild
type aB-crystallin at 45 °C, suggesting that the R120G aB-
crystallin already existed in a more open, even partially un-
folded, conformation at 25 °C. In the closely related protein,
aA-crystallin, mutation of the equivalent arginine residue
(Arg-116) to a cysteine and subsequent spin label modification
also changed the secondary, tertiary and quaternary structure
of the protein (52). The R120G mutation in aB-crystallin mod-
ified the protein structure such that the accessibility of the
chymotryptic sites was increased (Fig. 5).
Changes in the quaternary structure were therefore ex-
pected and this is substantiated by the results obtained from
size exclusion chromatography. The R120G mutation induced
an increase in the average Mr and a broadening of the Mr range
of aB-crystallin. A similar effect upon the Mr and therefore the
quaternary structure of aA-crystallin was also observed (21,
52) when the equivalent arginine (Arg-116) was changed. In
the case of HSP27, oligomerization of the a-crystallin domain
(21) was affected by mutating the equivalent arginine (Arg-
140), but here the Mr decreased. Obviously, while it can be
concluded that this conserved arginine performs a key struc-
tural role, the effect of changing this residue is not necessarily
the same for all the different sHSPs.
arrows). Co-aggregation between intermediate filaments and R120G aB-crystallin particles was seen (B, arrows). In the absence of intermediate
filaments, wild type (C) and R120G aB-crystallin (D) both formed discrete 15–20-nm particles (arrowheads). Bar 5 100 mm.
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The R120G Mutation Affects the Stability of aB-crystallin at
Elevated Temperatures—At elevated temperatures it has been
shown that a-crystallin adopts a more disordered structure
(53). A conformational transition with a midpoint at 60–62 °C
was observed by Fourier-transform infrared spectroscopy, dif-
ferential scanning calorimetry, and circular dichroism (53).
Using the latter method and monitoring the temperature de-
pendence of ellipticity at 205 and 217 nm, a gradual transition
was observed for wild type, but not R120G aB-crystallin, over
the temperature range of 25–55 °C (see also Fig. 2A). Thus, in
contrast to a-crystallin (50, 53), consisting of aA- and aB-
crystallin subunits, aB-crystallin alone does show a gradual
conformational transition in this temperature range. This is
not seen for R120G aB-crystallin, as expected from comparing
the CD spectra at 25 and 45 °C, which are very similar (Fig.
2B). At 64.5 °C and 57.2 °C, however, the heat-induced precip-
itation of wild type and R120G aB-crystallin, respectively, was
50% complete as measured by light scattering. The different
profile of temperature-induced protein aggregation of R120G
aB-crystallin compared with wild type aB-crystallin may re-
flect the increased polydispersity of the mutant protein com-
plexes, but this needs further experimentation.
These data do indicate, however, that aB-crystallin is first
stabilized by aA-crystallin, as a-crystallin does not precipitate
even at 100 °C (54). Second, these data indicate that the mu-
tation has increased the susceptibility of the protein to temper-
ature-induced unfolding leading to protein precipitation (Fig.
4). Therefore, the mutation decreases protein stability, but the
effects are most readily seen at non-physiological tempera-
tures. Nevertheless, the more important question is whether
these structural and stability changes caused by the R120G
mutation affect the biological activity of aB-crystallin.
Previous studies made a very important correlation between
structural changes in a-crystallin proteins and their chaperone
activity (12, 50, 55). Using hydrophobic probes, a transition at
30 °C was identified. The exposure of these hydrophobic sur-
faces was correlated with an increase in the observed chaper-
one activity of the a-crystallin proteins (12, 50). It has been
suggested that the polydisperse quaternary structure of aB-
crystallin oligomers (56) is an important feature of the chaper-
one activity (12). In other studies on aA-crystallin, however, it
has been possible to uncouple the changes in secondary and
quaternary structure from the chaperone activity (52). Thus,
although the R120G mutation causes changes in the protein
structure and stability, it is important to assess the effect of the
mutation upon the chaperone function of aB-crystallin.
Effect of R120G Mutation upon aB-crystallin Activity—In
vitro assays (9) have been developed to study the protein chap-
erone function of aB-crystallin utilizing the ability of aB-crys-
tallin to protect other proteins against either heat- or chemi-
cally induced denaturation (e.g. Refs. 10 and 11). These
proteins do not necessarily represent physiological targets for
the chaperone function of aB-crystallin, but they have allowed
this key function to be studied in vitro. The studies presented
here demonstrate that the chaperone function of aB-crystallin
is significantly compromised, although not completely abol-
ished toward these non-physiological substrates (Table I). In
fact, it appeared that R120G-aB-crystallin was a major part of
the insoluble pellet with both alcohol dehydrogenase and cit-
rate synthase as target proteins (data not shown), as also
reported for lactalbumin (49), suggesting that binding does not
absolutely correlate with chaperone activity.
Although these are important assays, they do not address
the most obvious feature of DRM, which is the collapse of the
intermediate filament network into characteristic aggregates
containing aB-crystallin (3, 4). Several in vitro assays were
used to investigate the effects of aB-crystallin on intermediate
filaments (27, 30, 32). The results presented here show some
loss in the ability of R120G aB-crystallin to inhibit intermedi-
ate filament assembly (Fig. 6), but the most dramatic changes
concerned the interaction of R120G aB-crystallin with assem-
bled intermediate filaments. First, the mutation caused aB-
crystallin to bind more avidly to intermediate filaments (Fig.
7). Second, R120G aB-crystallin could no longer prevent gel
formation by intermediate filaments (Table II). The increase in
binding was visualized (Fig. 8) in the negatively stained sam-
ples of the intermediate filament-aB-crystallin complexes
formed at 37 °C. In the presence of wild type aB-crystallin,
limited binding to the assembled intermediate filaments was
observed (Fig. 8A). In stark contrast, the R120G aB-crystallin
bound avidly to the assembled intermediate filaments and even
appeared to induce filament clumping (Fig. 8B). Filament
lengths were comparable in both samples and so, as expected
from the sedimentation assay results (Fig. 8; see also Ref. 57),
the differences in the solution viscosity were entirely due to the
different aB-crystallins. The data show the mutation in aB-
crystallin affects all the different aspects of the interaction
with intermediate filaments, but the key aspect would appear
to be the change in the activity of aB-crystallin with respect to
assembled intermediate filaments. The mutation caused in-
creased binding to intermediate filaments, which appears to
actively encourage filament-filament interactions. We propose
that this, coupled with the loss of the ability of R120G aB-
crystallin to prevent those filament-filament interactions seen
in the viscosity assay gels, will lead to intermediate filament
aggregation. Our observations are supported by the disease
pathology that is typified by intermediate filament aggregation
coupled with the association of aB-crystallin (3). It is important
to realize that both mutations in aB-crystallin and intermedi-
ate filament proteins cause such characteristic pathologies.
Our data suggest that a similar change in the association of
sHSPs as caused by intermediate filament mutations will ex-
plain these disease pathologies.
The R120G mutation in aB-crystallin obviously compromises
aB-crystallin function in vivo, but the disease phenotypes were
not seen at birth, appearing only in early adulthood (3) and
affecting only the lenses and muscles of individuals carrying
the mutation, while the other tissues that express aB-crystallin
had no phenotype. Several factors could explain these observa-
tions. First, both wild type and R120G aB-crystallin will be
expressed together (3). Second, the R120G mutation appar-
ently does not completely abolish the chaperone activity (Table
I). Finally, both the eye lens (58) and muscle express other
sHSPs, sometimes in high concentrations (59, 60), which could
change the sensitivity of the different tissues. Collectively,
these factors might help delay the onset of the disease and
select the eye lens and muscles as those tissues to be affected
by the R120G mutation in aB-crystallin.
Note Added in Proof—Similar effects on the structure and insulin-
chaperone activity of aA-crystallin were observed when the equivalent
arginine (Arg116) was mutated to cysteine (61).
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